Transcenta Presents Two Preclinical Studies at AACR 2023
SUZHOU, China, Apr.18, 2023, Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, has presented two preclinical study results of TST003, a First-in-Class mAb Targeting GREMLIN-1, and TST010, an ADCC enhanced anti-CD25 mAb as posters at the American Association for Cancer Research (AACR) Annual Meeting 2023. The full text of posters is available on Transcenta's website: https://www.transcenta.com/news/Industry_News